<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0036-3634</journal-id>
<journal-title><![CDATA[Salud Pública de México]]></journal-title>
<abbrev-journal-title><![CDATA[Salud pública Méx]]></abbrev-journal-title>
<issn>0036-3634</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0036-36342011000700006</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Heterogeneous distribution of hepatitis B serological markers in rural areas of Mexico]]></article-title>
<article-title xml:lang="es"><![CDATA[Distribución heterogénea de marcadores serológicos de hepatitis B en áreas rurales de México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[Luis A]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[Felipe Javier]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conde-González]]></surname>
<given-names><![CDATA[Carlos Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Programa de VIH/SIDA  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,El Colegio de la Frontera Norte  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2011</year>
</pub-date>
<volume>53</volume>
<fpage>S26</fpage>
<lpage>S31</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0036-36342011000700006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0036-36342011000700006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0036-36342011000700006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[OBJECTIVE: To study the distribution of the hepatitis B antibody (anti-HBc) based on a national serosurvey from 10 Mexican states showing a mean HBV prevalence higher than the national one. MATERIALS AND METHODS: This was a cross-sectional study. During 2003, anti-HBc was analyzed at INSP in 19 907 sera, and the related sociodemographic factors were determined. RESULTS: Anti-HBc prevalence was greater among men, but it was also associated to age, residence in a rural area, low socio-economic status, and illiteracy. Clusters of very high anti-HBc prevalence were found in several rural communities where the prevalence of anti-HBc in adults is 3 to 20 times the national average. CONCLUSIONS: Besides a low endemicity of HBV in Mexico, distribution is heterogeneous as was shown in several of the states studied, where there are rural towns with very high prevalence of HBV markers. National serosurveys are useful tools for identifying communities with hepatitis B hyperendemicity, where focused research and control measures are needed.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[OBJETIVO: Estudiar la distribución de anti-HBc en 10 estados con prevalencia mayor a la media nacional en la ENSA 2000. MATERIAL Y MÉTODOS: Durante 2003 se analizó en el INSP anti-HBc en 19 907 muestras de suero, se determinaron factores sociodemográficos relacionados. RESULTADOS: La prevalencia de anti-HBc fue mayor en hombres. Se asoció con la edad, residencia en áreas rurales, bajo nivel socioeconómico y analfabetismo. Se encontraron agrupamientos de alta prevalencia de anti-HBc en comunidades rurales en las cuales la prevalencia de anti-HBc en adultos está entre 3 y 20 veces por arriba de la media nacional. CONCLUSIONES: Contrastando con la baja endemicidad del VHB en México, su distribución es heterogénea. En varios estados se hallaron localidades rurales con muy alta prevalencia de anti-HBc. Las encuestas de salud permiten identificar comunidades donde la hepatitis B es hiperendémica y en las cuales se requiere enfocar la investigación y tomar medidas de control.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Hepatitis B]]></kwd>
<kwd lng="en"><![CDATA[rural Mexico]]></kwd>
<kwd lng="en"><![CDATA[anti-HBc]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
<kwd lng="es"><![CDATA[hepatitis B]]></kwd>
<kwd lng="es"><![CDATA[México rural]]></kwd>
<kwd lng="es"><![CDATA[anti-HBc]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINALS  ARTICLES</b></font></p>    <p>&nbsp;</p>    <p><a name="top1"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Heterogeneous  distribution of hepatitis B serological markers in rural areas of Mexico</b></font></p>    <p>&nbsp;</p>    <p><B><FONT SIZE="3" FACE="Verdana, Arial, Helvetica, sans-serif">Distribuci&oacute;n  heterog&eacute;nea de marcadores serol&oacute;gicos de hepatitis B en &aacute;reas  rurales de M&eacute;xico</FONT></B></p>    <p>&nbsp;</p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Luis  A Ju&aacute;rez-Figueroa, MD<sup>I</sup>; Felipe Javier Uribe-Salas, MD,DSc<sup>II</sup>;  Carlos Jes&uacute;s Conde-Gonz&aacute;lez, M Sc, PhD<sup>III</sup></b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Programa  de VIH/SIDA de la Ciudad de M&eacute;xico    <br> <sup>II</sup>El Colegio de la Frontera  Norte, M&eacute;xico    <br> <sup>III</sup>Instituto Nacional de Salud P&uacute;blica,  M&eacute;xico</font></p>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#end">Address  reprint requests to</a></font></p>    <p>&nbsp;</p>    <p>&nbsp;</p><hr size="1" noshade>     <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b>  To study the distribution of the hepatitis B antibody (anti-HBc) based on a national  serosurvey from 10 Mexican states showing a mean HBV prevalence higher than the  national one.    <br> <b>MATERIALS AND METHODS:</b> This was a cross-sectional study.  During 2003, anti-HBc was analyzed at INSP in 19 907 sera, and the related sociodemographic  factors were determined.    <br> <b>RESULTS:</b> Anti-HBc prevalence was greater among  men, but it was also associated to age, residence in a rural area, low socio-economic  status, and illiteracy. Clusters of very high anti-HBc prevalence were found in  several rural communities where the prevalence of anti-HBc in adults is 3 to 20  times the national average.    <br> <b>CONCLUSIONS:</b> Besides a low endemicity of  HBV in Mexico, distribution is heterogeneous as was shown in several of the states  studied, where there are rural towns with very high prevalence of HBV markers.  National serosurveys are useful tools for identifying communities with hepatitis  B hyperendemicity, where focused research and control measures are needed.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b>  Hepatitis B; rural Mexico; anti-HBc; Mexico</font></p><hr size="1" noshade>     <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMEN</b></font></p>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO:</b>  Estudiar la distribuci&oacute;n de anti-HBc en 10 estados con prevalencia mayor  a la media nacional en la ENSA 2000.    <br> <b>MATERIAL Y M&Eacute;TODOS:</b> Durante  2003 se analiz&oacute; en el INSP anti-HBc en 19 907 muestras de suero, se determinaron  factores sociodemogr&aacute;ficos relacionados.    <br> <b>RESULTADOS:</b> La prevalencia  de anti-HBc fue mayor en hombres. Se asoci&oacute; con la edad, residencia en  &aacute;reas rurales, bajo nivel socioecon&oacute;mico y analfabetismo. Se encontraron  agrupamientos de alta prevalencia de anti-HBc en comunidades rurales en las cuales  la prevalencia de anti-HBc en adultos est&aacute; entre 3 y 20 veces por arriba  de la media nacional.    <br> <b>CONCLUSIONES:</b> Contrastando con la baja endemicidad  del VHB en M&eacute;xico, su distribuci&oacute;n es heterog&eacute;nea. En varios  estados se hallaron localidades rurales con muy alta prevalencia de anti-HBc.  Las encuestas de salud permiten identificar comunidades donde la hepatitis B es  hiperend&eacute;mica y en las cuales se requiere enfocar la investigaci&oacute;n  y tomar medidas de control.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palabras  clave:</b> hepatitis B; M&eacute;xico rural; anti-HBc; M&eacute;xico </font></p><hr size="1" noshade>      <p>&nbsp;</p>    <p>&nbsp;</p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The  infection caused by the hepatitis B virus (HBV) has adifferent epidemiologic,  demographic and geographic distribution in human populations. Some authors havedocumented<sup>1,2</sup>  that in the Americas, Mexico is still a low endemic country regarding the HBV  infection, and theprevalence of HBV carriers in our country has been low. The  first Mexican national serological survey conductedin 1974 used the HbsAg marker,  and it estimated that 0.3% of the general population corresponded to HBV carriers.<sup>3</sup>  Even among persons with high-risk sexual behavior, such as commercial sex workers,  the prevalence of the <i>s</i> viral antigen has been low, ranging from 0.2% in  1988 to 0.8% in 1998.<sup>4-7</sup> Women seeking HIV antibodies testing during  1992 in Mexico City showed an HBsAg prevalence of 0.2%.<sup>8</sup> Among college  students from the state of Nuevo Leon, theglobal HBsAg seroprevalence was 0.39%  in 1996.<sup>9</sup></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">HBV  carriers in Mexico can be found among men who have sex with men and, to a lesser  extent, among care workers. One study carried out in Mexico City reportedthe following  HBsAg prevalences according to the sexual practices of men: among men who have  sex only with females, 0.3%; among those who have sex with femalesand males 1.1%;  and among those who have sex onlywith males, 4.8%.<sup>10</sup> Furthermore, one  multicentric surveyamong 935 care workers in Mexico reported a global HBsAg prevalence  of 1.2% with variations in terms ofoccupation: nurses, 0.6%; odontologists, 1.5%;  physicians,2%; and laboratory technicians, 2.5%.<sup>11</sup></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">HBV  transmission by blood transfusion decreased when the Mexican government banned  the commercialization of blood and established blood screening usingHBsAg detection.  Once this practice became compulsory in 1986, this form of HBV transmission was  virtuallyeliminated.<sup>12,13</sup> Further studies among blood donors in Mexico  have reported HBsAg prevalences ranging from 0.13% to 0.34%.<sup>14-16</sup></font></p>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Some  years ago in Mexico, anti-HBc and HBsAgmarkers from the 2000 National Health Survey  (ENSA2000), a nationwide population-based survey, were analyzed. Overall HBV seroprevalence  with both markerswas 3.3% and 0.21%, respectively.<sup>17</sup> In this regard,  a questionthat has not been answered yet is whether the distribution of the HBV  infection is homogeneous in Mexico. The present study analyzes characteristics  associated with theHBV infection in the 10 states whose anti-HBc prevalenceamong  adults is greater than 5%, i.e., 1.7 percent points higher than the national average.  Anti-HBc is a markerthat identifies individuals with previous or current HBV infection,  and it constitutes an epidemiological tool toestimate the prevalence of exposure  to HBV infection in the population. We hypothesize that the HBV infection in the  Mexican population is not homogenous, and that one indicator of this assertion  is that variations in HBV seroprevalence as assessed by anti-HBc testing depend  on urban versus rural residence.</font></p>    <p>&nbsp;</p>    <p><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Materials  and Methods</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Study  design and selection of the population</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The  ENSA 2000 studied a multistage stratified cluster sample of non-institutionalized  civilian population of Mexico including children (0-9 years of age), adolescents  (10-19 years of age) and adults (<u>&gt;</u> 20 years of age). The final sample  size of the survey was useful to make estimations both at national and state level  regarding the 32 federalentities or states that constitute the country.<sup>18</sup>  The 90 916 persons selected from the sample frame (26.6% children, 23.5% adolescents  and 49.8% adults) were interviewedat their home and a blood sample was taken from  each after an informed consent had been signed.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">There  were 83 157 serum samples available (91.4%) from all the individuals interviewed.<sup>18</sup>  For this study we selected all the subjects from the adolescent and adultpopulations  of those states whose anti-HBc prevalence among adults was higher than 5% with  respect to the sample frame of the ENSA 2000. The distribution of population by  state and the prevalence of the Anti-HBc marker by state and by age group are  shown in <a href="/img/revistas/spm/v53s1/a06tab01m.jpg">Table I</a>. The final  number of samples analyzed in this study (n = 19 898) represented almost one third  of the total samples collected by the ENSA 2000.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Questionnaire,  variables and ethical considerations</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The  ENSA 2000 obtained information on the following issues: socio-demographic characteristics  of the population; risk factors for chronic diseases; biological markers of infectious  diseases; and access, use and coverage of health service programs.<sup>18</sup>  For this work, the following socio-demographic characteristics of the adult population  were studied: age, sex, place of residence, literacy, and goods index. The protocol  for this study was approved by the Ethics Committee at the National Institute  of Public Health (INSP) in Mexico, and the data were gathered under the confidential  principles stated by the Statistical and Geographical Information Law.<sup>19</sup></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Estimation  of seroprevlaence of HBV and laboratory analyses</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Anti-HBc  was used as a marker of previous and/or current HBV infection among 6 378 adolescents  (10-19 years of age) and 13 520 adults (<u>&gt;</u> 20 years of age). Preliminary  sample screening for anti-HBc was conducted at INSP using pooled samples (aliquots  of equal volume) of three sera. Anti-HIV was also assessed in the same pooled  samples. Single sera of all positive pooled samples were afterwards analyzed to  determine individual seropositivity.</font></p>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Statistical  analyses</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">A  descriptive analysis was performed to estimate the prevalence of anti-HBc by stratifying  the variables by sex and by state. To estimate the magnitude of the association  between anti-HBc prevalence and the study variables, we calculated prevalence  odds ratios and their corresponding confidence intervals. We conducted crude and  multivariate analyses using a logistic regression model that included all the  study variables. These data analyses were performed using the STATA 9.0 software.<a name="1b"></a><sup><a href="#1a">*</a></sup>  A map was drawn using the geographical information system Arc View 9.0 to project  the geographic distribution of anti-HBc antibody among adults at a municipal level  (<a href="#fig2">Figure 2</a>).</font></p>    <p><a name="fig1"></a></p>    <p>&nbsp;</p>    <p align="center"><img src="/img/revistas/spm/v53s1/a06fig01.jpg"></p>    <p>&nbsp;</p>    <p><a name="fig2"></a></p>    <p>&nbsp;</p>    <p align="center"><img src="/img/revistas/spm/v53s1/a06fig02.jpg"></p>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">We  studied 19 898 individuals out of which 13 520 (68%)were adults. The global prevalence  of anti-HBc among young people aged 10 to 19 in the ten states studied was 0.7%,  while among individuals aged 20 or more it was 8.0%. The prevalence of anti-HBc  among adolescents and adults stratified by state is shown in <a href="/img/revistas/spm/v53s1/a06tab01m.jpg">Table  I</a>. Prevalence increased with age, from less than 1% in the 10 to 14 years-of-age  group to 36% in the group &gt; 75 years of age (<a href="#fig1">Figure 1</a>).  Only two of the anti-HBc positive individuals (from a total of 1 130) were also  found to be anti-HIV positive (0.18%).</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Prevalence  of anti-HBc among adults was significantly greater in men than in women. Anti-HBc  positivity was also associated with age, residence in a rural area, low socio-economic  status and lack of education (<i>p</i> &lt; 0.001) (<a href="/img/revistas/spm/v53s1/a06tab02m.jpg">Table  II</a>).</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">When  distribution of prevalence of the anti-HBc marker was analyzed with respect to  the rural communities in the selected states, the results show that in twelve  communities belonging to seven of the studied states prevalence among adults was  higher than 31% (<a href="#tab3">Table III</a>). Three communities from the state  of Guerrero displayed the highest prevalences, ranging from 72% to 90%. Other  states displayed lower prevalences than Guerrero, butthey were nevertheless much  higher than the average reported among the adult population by the ENSA 2000 (3.3%).<sup>17</sup>  The third column in <a href="#tab3">Table III</a> represents the total population  of communities according to the 12<sup>th</sup> National Census of Population  and Housing performed in 2000.The number of inhabitants points to their rural  character.Prevalences were estimated by using information from the ENSA 2000 sample  frame (data no shown). <a href="#fig2">Figure 2</a> represents a quite heterogeneous  distribution of anti-HBcprevalences within each state studied.</font></p>    <p><a name="tab3"></a></p>    <p>&nbsp;</p>    <p align="center"><img src="/img/revistas/spm/v53s1/a06tab03.jpg"></p>    <p>&nbsp;</p>    <p><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Results  from the ENSA 2000 samples indicate that the highest HBV prevalence is observed  along the Pacific coast, the southern border region, and in the states south of  the Gulf of Mexico. This distribution pattern was first observed in 1974 following  Mexico's first national seroepidemiological survey.<sup>3</sup> Data presented  herein indicate that distribution of HBV in Mexico is heterogeneous with apparent  rural clusters. Very low and very high prevalence counties may be found within  the same state (<a href="#fig2">Figure 2</a>).</font></p>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Anti-HBc  prevalence increases significantly fromadolescence onwards, which suggests that  HBV transmission in Mexico most likely concurs with the onset of sexual relations.  Among adults, HBV affects men more than women, which points to the existence of  a differential risk, associated with sexual-related behaviors not studied by the  ENSA2000.Anti-HBc prevalence is higher in rural areas than in urban ones, and  it is associated with age, lack of schooling and low socio-economic status.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In  the 10 states (from ENSA 2000), only two out of the 1 130 individuals found to  be anti-HBc positive also tested positive for anti-HIV antibodies (0.18%), suggesting  that the behavior of the AIDS epidemic in this group is not different from the  one observed in the population at large.<sup>20</sup> Other population groups  in Mexico, however, such as urban men who have sex with men, show high prevalence  for both HBV and HIV.<sup>10</sup> In such groups, the presence of one of these  infections predicts the other, since they are both associated to the same risky  sexual behavior as has been demonstrated in cohort studies.<sup>21,22</sup></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Rural  communities where anti-HBc prevalences were 3 to 20 times higher than the national  average were identified based on the ENSA 2000. A very high prevalence of HBV  serological markers was further confirmed in two of these rural villages, Calera  and Cuambio (<a href="#tab3">Table III</a>,) where an average anti-HBc prevalence  of 50.5% was found in a larger sample from the population &gt; 11 years of age.<sup>23</sup></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Given  the large proportion of clustered individuals testing positive for anti-HBc antibodies,  an alternative hypothesis regarding the iatrogenic transmission of the virus mainly  in rural areas could point to the reuse of syringes and needles. The World Health  Organization has warned that on a daily basis, unsafe injections cause a steady  number of unrecognized transmissions of blood-borne infections in developing countries,  and that the distribution of such injections appears to be strongly clustered  within the population of each country,<sup>24</sup> which is consistent with the  HBV distribution pattern found in this study. Carrying on with the study of these  and other communities, using tools such as ethnographic descriptions, in-depth  interviews and identification of key informants from each community in order to  better understand the role of unsafe injections, risky sexual behavior, migration  and other factors in the spread of the VHB infection might prove to be appropriate.  Since universal hepatitis B vaccination of newborns started in Mexico in 1999,  vaccination against hepatitis B for those aged over 10 in these high-prevalence  communities is expected to be minimal, and it points to the urgent need to offer  such vaccination to adolescents and young adults in the communities studied.</font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">In  conclusion, national health surveys are an ideal tool to identify populations  at risk of hepatitis B. Unlike urban population groups with high concurrent prevalence  of HBV and HIV, such as men who have sex with men,<sup>10</sup> the hepatitis  B epidemic in rural areas has largely developed to date without the presence of  HIV. The older age groups are the most seriously affected, pointing to the historical  nature of the epidemic, which is probably in decline. However, the existence of  relatively isolated rural towns where conditions currently exist for HBV transmission,  as demonstrated by the presence of anti-HBc positivity among young people, reinforces  the need for a continued surveillance and for the implementation of preventive  interventions in such localities.</font></p>    <p>&nbsp;</p>    <p><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Acknowledgments</b></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">To  all the personnel of the Ministry of Health, Mexico and National Institute of  Public Health who participated in the ENSA2000. This study was financed by the  National Institute of Public Health, Mexico and CONACYT, M&eacute;xico (Salud  2002-C01-7975).</font></p>    <p>&nbsp;</p>    <p><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.  Hadler SC, Fay OH, Pinheiro F, Maynard JE. Hepatitis B in the Americas: Inform  of the PAHO collaborative group. Bol Oficina Sanit Panam. 1987;103:185-209.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328774&pid=S0036-3634201100070000600001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.  Silveira TR, da Fonseca JC, Rivera L, Fay OH,Tapia R, Santos JI, et al. Hepatitis  B Seroprevalence in Latin America. Pan Am J Public Health 1999;6:378-383.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328776&pid=S0036-3634201100070000600002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.  Landa L. Hepatitis B seroepidemiology. Gac Med Mex. 1976;111:108.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328778&pid=S0036-3634201100070000600003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.  Hyams CK, Escamilla J, Losada R, Macareno-Alvarado E, Bonilla-Giraldo N, Papaditos  TJ, et al. Hepatitis B infection in a non-drug abusing prostitute population.  Scand J Infect Dis 1990;22:527-531.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328780&pid=S0036-3634201100070000600004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.  Uribe-Salas F, Hern&aacute;ndez-Avila M, Conde-Glez C, Ju&aacute;rez-Figueroa  L, Allen B,Anaya-Ocampo R, et al. Low prevalence of HIV infection and sexually  transmitted disease among female commercial sex workers in Mexico City.Am J Public  Health 1997;87:1012-1015.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328782&pid=S0036-3634201100070000600005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.  Ju&aacute;rez-Figueroa L, Uribe-Salas F, Conde-Glez JC, Hernandez-Avila M, Olamendi-Portugal  M, Uribe-Zuninga P, et al. Low prevalence of hepatitis B markers among Mexican  commercial sex workers. Sex Transm Inf 1998;74:448-450.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328784&pid=S0036-3634201100070000600006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.  Uribe-Salas F, Conde-Glez C, Ju&aacute;rez-Figueroa L, Hern&aacute;ndez-Castellanos  A. Socio-demographic dynamics and sexually transmitted infections in female sex  workers from Mexican-Guatemalan border. Sex Transm Dis 2003;30:266-271.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328786&pid=S0036-3634201100070000600007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.  Hern&aacute;ndez-Gir&oacute;n C, Uribe-Salas F, Conde-Gonz&aacute;lez C, Cruz-Valdez  A, Ju&aacute;rez-Figueroa L, Uribe-Z&uacute;&ntilde;iga P, et al. Seroprevalence  to diverse virus and sociodemographic characteristics among women who seek HIV  detection. Rev Invest Clin 1997;49:5-13.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328788&pid=S0036-3634201100070000600008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.  Flores-Casta&ntilde;eda MS, Garc&iacute;a-M&eacute;ndez BL,Tijerina-Menchaca R.  Seropositivity to HCV and HBV among college students from Nuevo Leon State, Mexico.  Rev Gastroenterol Mex 1996;61:327-331.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328790&pid=S0036-3634201100070000600009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.  Ju&aacute;rez-Figueroa L, Uribe-Salas F, Conde-Glez CJ, Hern&aacute;ndez-Avila  M, Hern&aacute;ndez Nevaez P, Uribe-Z&uacute;&ntilde;iga P, et al. Hepatitis B  markers in men seeking human immunodeficiency virus antibody testing in Mexico  City. Sex Transm Dis 1997;24:211-217.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328792&pid=S0036-3634201100070000600010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.  Kershenobich D, Hurtado R, Collawn C, Bobadilla J, Cabrera G, Borovoy J, Borbolla  R, et al. Seroprevalence of hepatitis B among health workers. Multicentric study  in Mexico. Rev Invest Clin 1990;42:251-256.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328794&pid=S0036-3634201100070000600011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.  Secretar&iacute;a de Salud. Norma t&eacute;cnica para el uso terap&eacute;utico  de la sangre humana y sus componentes. Cap&iacute;tulo seis,Art&iacute;culo 14,  Fracci&oacute;n VII. M&eacute;xico: Secretar&iacute;a de Salud, 1986.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328796&pid=S0036-3634201100070000600012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.  Secretar&iacute;a de Salud. Norma t&eacute;cnica para el uso terap&eacute;utico  de la sangre humana y sus componentes. NOM-003-SSA2-1993. Cap&iacute;tulo 7, Art&iacute;culo  7.1.4. M&eacute;xico: Secretar&iacute;a de Salud, 1994. (consulted on September  2010). Disponible en <a href="http://www.salud.gob.mx" target="_blank">www.salud.gob.mx</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328798&pid=S0036-3634201100070000600013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.Alvarez-Mu&ntilde;oz  MT, Bustamante-Calvillo ME, Guiscafre-Gallardo JP, Mu&ntilde;oz O. Hepatitis B  and Delta: prevalence, seroepidemiological markers and familiar group. Gac Med  Mex 1991;127:399-404.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328800&pid=S0036-3634201100070000600014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.  Souto-Meri&ntilde;o CA, Sim&oacute;n-Dom&iacute;nguez J, Pulido-Priego ML, Mart&iacute;nez-  Perez A, Mart&iacute;nez-Mart&iacute;nez IC, del R&iacute;o-Chiriboga C, et al.  Prevalence of hepatitis A, B and C markers in one Mexican Hospital. Salud Publica  Mex 1994;36:257-262.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328802&pid=S0036-3634201100070000600015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.  Rivera-L&oacute;pez MR, Zavala-M&eacute;ndez C,Arenas-Esqueda A. Prevalence of  seropositivity to HIV, hepatitis B and C among blood donors. Gac Med Mex 2004;140:657-660.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328804&pid=S0036-3634201100070000600016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.  Valdespino JL, Conde-Gonz&aacute;lez CJ, Olaiz-Fern&aacute;ndez, G, Palma O, Sep&uacute;lveda  J. Prevalence in M&eacute;xico of hepatitis B infection and carrier status among  adults. Salud Publica Mex 2007;Vol. 49(sup 3):s404-s411.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328806&pid=S0036-3634201100070000600017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.  Sep&uacute;lveda, J,Tapia-Conyer, R,Vel&aacute;zquez, O,Valdespino, JL, Olaiz-  Fern&aacute;ndez, G, Kuri, P, <i>et al.</i> Salud Publica Mex 2007; 49 (Supl 3):  S427-S432.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328808&pid=S0036-3634201100070000600018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.  Diario Oficial de la Federaci&oacute;n. Ley de Informaci&oacute;n Estad&iacute;stica  y Geogr&aacute;fica, 1980. M&eacute;xico: diciembre 30, 1980. (consulted on March  27, 2007).Available on: <a href="http://www.ordenjuridico.gob.mx/Federal/PL/CU/Leyes/30121980(1).pdf" target="_blank">http://www.ordenjuridico.gob.mx/Federal/PL/CU/Leyes/30121980(1).pdf</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328810&pid=S0036-3634201100070000600019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20.  del R&iacute;o C, Sep&uacute;lveda J.AIDS in Mexico: lessons learned and implications  for developing countries.AIDS 2002;16:1445-1457.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328812&pid=S0036-3634201100070000600020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21.  Kingsley L, Rinaldo C, Lyter D,Valdiserri RO, Belle SH, Ho M et al. Sexual transmission  efficiency of hepatitis B virus and human immunodeficiency virus among homosexual  men. JAMA. 1990;264:230-234.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328814&pid=S0036-3634201100070000600021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22.  Chimel J, Detels R, Kaslow R,Van Raden M, Kingsley LA, Brookmeyer R. Factors associated  with prevalent human immunodeficiency virus infection in the Multicenter AIDS  Cohort Study (MACS).Am J Epidemiol. 1987;126:568-577.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328816&pid=S0036-3634201100070000600022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23.  Ju&aacute;rez-Figueroa L, Conde-Glez C, Uribe-Salas F, Guerrero- Lemus V. Hepatitis  B virus (HBV) serology in high-prevalence rural communities of Guerrero State,  Mexico. XVI Congress of the International Society for Sexually Transmitted Diseases  Research. Amsterdam, July 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328818&pid=S0036-3634201100070000600023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.  Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing  world and transmission of bloodborne pathogens: a review. Bull World Health Organ.  1999;77:789-800.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=9328820&pid=S0036-3634201100070000600024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <p>&nbsp;</p>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p><a name="end"></a><a href="#top1"><img src="/img/revistas/spm/v53s1/seta.jpg" border="0"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif">  <b>Address reprint requests to:</b>    <br> Dr. Luis Ju&aacute;rez-Figueroa    <br> Laboratorio  de VIH/ETS, Programa de VIH/SIDA, Ciudad de M&eacute;xico    <br> Benjam&iacute;n  Hill 24, Col. Condesa    <br> 06140 M&eacute;xico DF    <br> E-mail: <a href="mailto:luisjuarez@insp.mx">luisjuarez@insp.mx</a></font></p>    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Received  on: October 21, 2010    <br> Accepted on: May 25, 2011    <br> <i>Declaration of conflicts  of interest:</i> The authors declare no conflict of interest</font></p>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p>&nbsp;</p>    <p><a name="1a"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#1b">*</a>  Stata Survey Data, 2003. Reference Manual. Release 8, Stata Corporation, United  States of America</font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hadler]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Fay]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maynard]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B in the Americas: Inform of the PAHO collaborative group]]></article-title>
<source><![CDATA[Bol Oficina Sanit Panam]]></source>
<year>1987</year>
<volume>103</volume>
<page-range>185-209</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[da Fonseca]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fay]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Tapia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B Seroprevalence in Latin America]]></article-title>
<source><![CDATA[Pan Am J Public Health]]></source>
<year>1999</year>
<volume>6</volume>
<page-range>378-383</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B seroepidemiology]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>1976</year>
<volume>111</volume>
<page-range>108</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyams]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Escamilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Losada]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Macareno-Alvarado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bonilla-Giraldo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Papaditos]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B infection in a non-drug abusing prostitute population]]></article-title>
<source><![CDATA[Scand J Infect Dis]]></source>
<year>1990</year>
<volume>22</volume>
<page-range>527-531</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Avila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Glez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Anaya-Ocampo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Low prevalence of HIV infection and sexually transmitted disease among female commercial sex workers in Mexico City]]></article-title>
<source><![CDATA[Am J Public . Health]]></source>
<year>1997</year>
<volume>87</volume>
<page-range>1012-1015</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Glez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez-Avila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olamendi-Portugal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Zuninga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Low prevalence of hepatitis B markers among Mexican commercial sex workers]]></article-title>
<source><![CDATA[Sex Transm Inf]]></source>
<year>1998</year>
<volume>74</volume>
<page-range>448-450</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Glez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Castellanos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Socio-demographic dynamics and sexually transmitted infections in female sex workers from Mexican-Guatemalan border]]></article-title>
<source><![CDATA[Sex Transm Dis]]></source>
<year>2003</year>
<volume>30</volume>
<page-range>266-271</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Girón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-González]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Valdez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Zúñiga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Seroprevalence to diverse virus and sociodemographic characteristics among women who seek HIV detection]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>1997</year>
<volume>49</volume>
<page-range>5-13</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores-Castañeda]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[García-Méndez]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Tijerina-Menchaca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Seropositivity to HCV and HBV among college students from Nuevo Leon State, Mexico]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>1996</year>
<volume>61</volume>
<page-range>327-331</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Glez]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Avila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Nevaez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Zúñiga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B markers in men seeking human immunodeficiency virus antibody testing in Mexico City]]></article-title>
<source><![CDATA[Sex Transm Dis]]></source>
<year>1997</year>
<volume>24</volume>
<page-range>211-217</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kershenobich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Collawn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bobadilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Borovoy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borbolla]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Seroprevalence of hepatitis B among health workers: Multicentric study in Mexico]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>1990</year>
<volume>42</volume>
<page-range>251-256</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Norma técnica para el uso terapéutico de la sangre humana y sus componentes: Capítulo seis,Artículo 14, Fracción VII]]></source>
<year>1986</year>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Norma técnica para el uso terapéutico de la sangre humana y sus componentes: NOM-003-SSA2-1993. Capítulo 7, Artículo 7.1.4]]></source>
<year>1994</year>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez-Muñoz]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Bustamante-Calvillo]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Guiscafre-Gallardo]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatitis B and Delta: prevalence, seroepidemiological markers and familiar group]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>1991</year>
<volume>127</volume>
<page-range>399-404</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souto-Meriño]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Simón-Domínguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pulido-Priego]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez- Perez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Martínez]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[del Río-Chiriboga]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of hepatitis A, B and C markers in one Mexican Hospital]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>1994</year>
<volume>36</volume>
<page-range>257-262</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera-López]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Zavala-Méndez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas-Esqueda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of seropositivity to HIV, hepatitis B and C among blood donors]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2004</year>
<volume>140</volume>
<page-range>657-660</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdespino]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-González]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olaiz-Fernández]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sepúlveda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence in México of hepatitis B infection and carrier status among adults]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2007</year>
<volume>49</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>s404-s411</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sepúlveda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tapia-Conyer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Velázquez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Valdespino]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Olaiz- Fernández]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kuri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2007</year>
<volume>49</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S427-S432</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>Diario Oficial de la Federación</collab>
<source><![CDATA[Ley de Información Estadística y Geográfica, 1980]]></source>
<year>dici</year>
<month>em</month>
<day>br</day>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[del Río]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sepúlveda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AIDS in. Mexico: lessons learned and implications for developing countries]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2002</year>
<volume>16</volume>
<page-range>1445-1457</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kingsley]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rinaldo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lyter]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valdiserri]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Belle]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1990</year>
<volume>264</volume>
<page-range>230-234</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chimel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Detels]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kaslow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Van Raden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kingsley]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Brookmeyer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Factors associated with prevalent human immunodeficiency virus infection in the Multicenter AIDS Cohort Study (MACS)]]></article-title>
<source><![CDATA[Am. J Epidemiol]]></source>
<year>1987</year>
<volume>126</volume>
<page-range>568-577</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juárez-Figueroa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Conde-Glez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Salas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero- Lemus]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatitis B virus (HBV) serology in high-prevalence rural communities of Guerrero State, Mexico]]></source>
<year></year>
<conf-name><![CDATA[XVI Congress of the International Society for Sexually Transmitted Diseases Research]]></conf-name>
<conf-date>July 2005</conf-date>
<conf-loc>Amsterdam </conf-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simonsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zaffran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Unsafe injections in the developing world and transmission of bloodborne pathogens: a review]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>1999</year>
<volume>77</volume>
<page-range>789-800</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
